CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01)

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 244-248

  Pestalozzi, Bernhard C ^a   Holmes, Eileen ^b   de Azambuja, Evandro ^c   Metzger Filho, Otto ^d   Hogge, Laurence ^c   Scullion, Matt ^e   Láng, István ^f   Wardley, Andrew ^g   Lichinitser, Mikhail ^h   Sanchez, Roberto I Lopez ⁱ   Müller, Volkmar ^j   Dodwell, David ^k   Gelber, Richard D ^m   Piccart Gebhart, Martine J ^c   Cameron, David ^d,l  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^c JULES BORDET INSTITUTE   (Belgium)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ Isthmian Medical Research Centre SA   (Panama)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

^m WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HER2 POSITIVE EARLY BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84875236228     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70017-2     Document Type: Article

References (21)

1. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12:236-244.
2. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008, 19:1090-1096.
3. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
6. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
7. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
8. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003, 14:1072-1077.
9. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944.
10. Tsukada Y, Fouad A, Pickren JW, Lane WW Central nervous system metastasis from breast carcinoma: autopsy study. Cancer 1983, 52:2349-2354.
11. Pestalozzi BC, Francis P, Quinaux E, et al. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 Trial. Ann Oncol 2008, 19:1837-1841.
12. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977.
13. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91:639-643.
14. Lai R, Dang CT, Malkin MG, Abrey LE The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004, 101:810-816.
15. Leyland-Jones B Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286.
16. Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008, 109:231-239.
17. Gray RJ A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
18. Goldhirsch A, Piccart M, Procter M, et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. 37th European Society of Medical Oncology Congress; Vienna, Austria; Sept 28-Oct 2, 2012. LBA 6.
19. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer. Cancer 2011, 117:1837-1846.
20. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14:64-71.
21. Baselga J, Cortès J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.